A common and potent consideration has recently entered the landscape of the novel
coronavirus disease of 2019 (COVID-19): venous thromboembolism (VTE). COVID-19 has …

Background Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable
state and have an increased incidence of VTE. In response, CHEST issued rapid clinical …

Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months,
causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation …

The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening
multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with …

Background: Venous Thromboembolism (VTE) is common among patients with severe
Coronavirus Disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients …

Abstract Purpose of Review Novel coronavirus disease 2019 (COVID-19) has been
associated with an increased risk of arterial and venous thromboembolic (VTE) diseases …

Thrombotic complications from COVID-19 are now well known and contribute to significant
morbidity and mortality. Different variants confer varying risks of thrombotic complications …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Coronavirus disease 2019 (COVID-19) is a systemic disease that can be life-threatening
involving immune and inflammatory responses, and that can result in potentially lethal …

As the Coronavirus disease 2019 (COVID-19) pandemic spread to the US, so too did
descriptions of an associated coagulopathy and thrombotic complications. Hospitals created …